1. Dostarlimab for primary advanced or recurrent endometrial cancer;Mirza;N. Engl. J. Med.,2023
2. Pembrolizumab plus chemotherapy in advanced endometrial cancer;Eskander;N Engl J Med.,2023
3. Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Carboplatin and Paclitaxel in Women with Advanced/Recurrent Endometrial Carcinoma: ENGOT-en7/MaNGO/AtTEnd study;Colombo,2023
4. S.N. Westin, K. Moore, H.S. Chon, J.Y. Lee, J.T. Pepin, M. Sundborg, DUO-E investigator, et al., Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial, J. Clin. Oncol. Jan 2024:20;42(3)282-299.(PMID: 37864337).
5. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy in patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG3031/RUBY Trial;Mirza,2024